Inhaled Nitric Oxide Treatment for Aneurysmal SAH Patients With Intractable Cerebral Vasospasm
Status:
Completed
Trial end date:
2020-03-20
Target enrollment:
Participant gender:
Summary
Aneurysmal subarachnoid haemorrhage (aSAH) is a rare but severe subtype of stroke with high
mortality and morbidity. Besides rebleeding, delayed cerebral ischaemia and cerebral
vasospasm (CVS) are thought to be major reasons for the poor outcome in survivors of aSAH.
Despite advances in the detection and treatment of CVS 20-40% of CVS patients experience
cerebral Ischaemia. Experimental animal studies for ischaemic stroke, traumatic brain injury,
and SAH showed that inhaled nitric oxide (iNO) selectively dilates cerebral arteries and
arterioles in hypoperfused brain tissue. The investigators therefore performed this
prospective pilot study to evaluate the effects of iNO on cerebral perfusion in patients with
refractory vasospasm after aSAH.